The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Full results have not yet been published, but according to Amgen findings showed treatment with tezepelumab statistically significantly and clinically meaningfully reduced the size of nasal polyps and ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

A common ingredient found in most oral over-the-counter cold medicines should be removed from the market because it doesn’t ...

I recently took a generic 12-hour, maximum-strength nasal decongestant to manage typical sinus pressure and congestion.

The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient in over-the-counter drugs for nasal congestion, stating it ...

Participants in the trial were symptomatic despite treatment with standard of care (intranasal corticosteroids [INCS]). 1 Dr. Joseph Han, Vice Chair of Rhinology & Endoscopic Sinus and Skull Base ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the common ingredient phenylephrine off ...

Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...